Udit Nindra

Time toxicity associated with early phase clinical trial participation

Udit Nindra, Gowri Shivasabesan, Stacy J. Childs et al. · ESMO Open · 2023 · 34 citations · Full text

Medicine, Pharmacology, Good Clinical Practice +9

Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso

Nicholas McNamee, Catriona Harvey, Lauren Gray et al. · Journal of Thoracic Oncology · 2023 · 33 citations · Full text

Medicine, Immunology, Oncology +14

Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies

Adel Shahnam, Nadia Hitchen, Udit Nindra et al. · European Journal of Cancer · 2023 · 20 citations

Medicine, Biostatistics, Oncology +15

Elevated neutrophil‐to‐lymphocyte ratio (<scp>NLR</scp>) is associated with poorer progression‐free survival in unresectable stage <scp>III NSCLC</scp> treated with consolidation durvalumab

Udit Nindra, Adel Shahnam, Samuel Xavier Stevens et al. · Thoracic Cancer · 2022 · 16 citations · Full text

Medicine, Hematology, Oncology +12

Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer

Samuel Xavier Stevens, Udit Nindra, Adel Shahnam et al. · Journal of Geriatric Oncology · 2024 · 14 citations · Full text

Medicine, Geriatric Medicine, Oncology +17